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Aims & Objective:  
To compare the efficacy of Pharmacoinvasive therapy and Primary Angioplasty in 
STEMI patients. The objective was to  to study whether  the incidence of composite 
end points (mortality, cardiogenic shock and re-myocardial infarction) in 
Pharmacoinvasive strategy is non inferior to Primary Angioplasty in patients with 
STEMI. 
 Background: 
In STEMI patients the treatment of choice is primary PCI. (ACC/AHA Class IA 
recommendation).  But in real world situations, timely PCI remains a challenge 
especially  in developing countries like India where the number of centres performing 
PCI are few. Timely transfer to such centres also remains a huge challenge 
considering the dearth of emergency ambulance services and the state of our road 
infrastructure.  
Pharmacoinvasive strategy refers to routine angiography with a view to revascularize 
the infarct related vessel 3-24 hours after fibrinolysis. ACC/AHA has given a classIIa 
recommendation, while European society of Cardiology has given a class I 
recommendation for this strategy. We will look whether pharmacoinvasive strategy is 
non inferior to primary PCI (as proved in various trials) in a setting like ours where 
streptokinase is used as a fibrinolytic agent as compared to the western countries 
where these trials were conducted using tenecteplase as a fibrinolytic agent. 
Methods: 
137 patients were included in this study. All patients admitted with a diagnosis of   
STEMI at our centre, within a window period of 24 hours. Over a period of 9 months, 
who underwent PCI or pharmacoinvasive therapy was included in this study. Primary 
end points (death within 30 days, re-MI within 30 days, and cardiogenic shock) and 
secondary endpoints (arrhythmias, bleeding manifestations, ischemic stroke, ejection 
fraction, mechanical complications, duration of hospital stay) were looked into. 
 Results: 
Though the hypothesis was non-inferiority, analysis of composite of primary endpoint 
and mortality outcome suggested equivalence. There was no significant difference 
between the secondary outcomes between the two groups. Use of thrombus aspiration 
device and in turn the thrombus burden was significantly lower in the 
pharmacoinvasive group than in primary PCI arm. Pharmacoinvasive arm had 
significantly greater number of patients who presented with Anterior wall MI. 
 Conclusion: 
This is a small study, which showed that pharmacoinvasive therapy is as effective as 
primary PCI in the setting of STEMI. It can also be further inferred that, 
pharmacoinvasive strategy using streptokinase, is an effective alternative to 
tenecteplase, in our setting with no associated increase in adverse events. 
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